Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84575 | 0.90 | HTR2A (0.58) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL85231 | 0.88 | HTR2A (0.58) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL84574 | 0.87 | DRD2 (0.60) | HTR2AHTR7DRD2DRD3ACHE | |
| SCHEMBL85017 | 0.85 | DRD2 (0.48) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL84571 | 0.85 | HTR2A (0.54) | HTR2ADRD2HTR1ADRD3ACHE | |
| SCHEMBL85015 | 0.84 | DRD2 (0.65) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL84562 | 0.84 | DRD2 (0.53) | HTR2AHTR7DRD2HTR1A | |
| SCHEMBL21633562 | 0.83 | HTR2A (0.60) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL85004 | 0.82 | HTR2A (0.62) | HTR2AHTR7KCNH2DRD2HTR1A | |
| SCHEMBL10634285 | 0.82 | HTR2A (0.55) | HTR2AHTR7KCNH2DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |